Floatz logo

Carboplatin

Respiratory Tract Diseases

Nanfang Hospital, Southern Medical UniversitySmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Respiratory Tract Diseases cohort.

Asset / SponsorPhaseRating
N-Acetyl-L-Cysteine
Zambon SpA
Phase 3B
Ambroxol
Zambon SpA
Phase 3B
Vinorelbine
University of Turin, Italy
Phase 3B
Rivoceranib
Sichuan Cancer Hospital and Research Institute
Phase 2B
Docetaxel
University of Turin, Italy
Phase 3B

View all 14 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →